Journal of Clinical Endocrinology & Metabolism, Vol 40, 373-379, Copyright © 1975 by Endocrine Society

ARTICLES

Interaction of delta-5-androstene-3beta, 17beta-diol with estradiol and dihydrotestosterone receptors in human myometrial and mammary cancer tissue

J Poortman, JA Prenen, F Schwarz and JH Thijssen

Specific receptor binding of estradiol (E-2) and dihydrotestosterone (DHT) was studied in human myometrial tissue and in human mammary cancer tissue. The inhibition of binding for E-2 and DHT by E-2, testosterone (T), DHT, dehydroepiandosterone (DHEA), dehydroepiandrosterone-sulfate (DHEA-S), androstendione (A) and 5- androstene-3beta, 17beta-diol (Adiol) was tested with the use of dextran-coated charcoal separation of bound and free E-2, respectively, and DHT. The percentage of binding inhibition was calculated with reference to the inhibition obtained with nafoxidine in a molar concentration ratio of 1,000 for E-2 binding, respectively, with cyproterone acetate in a molar concentration ratio of 10,000 for DHT binding. In 15 samples of myometrium tested, receptors were found for both E-2 and DHT. From 19 samples of mammary carcinoma tissue one showed no binding activity, three samples did bind E-2 only, five samples DHT only, and ten samples showed binding of both steroids. A 50% inhibition of E-2 binding, in myometrial as well as in tumor tissue, required a molar concentration ratio of 40 for Adiol, of more than 2,000 for DHEA. No significant inhibiting activity could be found for A up to a molar concentration ratio of 10,000 and for DHEA-S up to 40,000. With regard to DHT binding, Adiol is more active than E-2 and less active than T. Of the substances tested Adiol is therefore the only one which exerts a significant inhibiting influence at a molar ratio not far beyond the physiological range. This signifies that Adiol might interfere at the receptor level in the estrogenic stimulation of mammary cancer cells.

This article has been cited by other articles:

				C Suarez, J Vela, I Garcia-Tornadu, and D Becu-Villalobos Dehydroepiandrosterone (DHEA) modulates GHRH, somatostatin and angiotensin II action at the pituitary level J. Endocrinol., April 1, 2005; 185(1): 165 - 172. [Abstract] [Full Text] [PDF]

				J. T. Arnold, H. Le, K. K. McFann, and M. R. Blackman Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells Am J Physiol Endocrinol Metab, March 1, 2005; 288(3): E573 - E584. [Abstract] [Full Text] [PDF]

				S. Toth-Fejel, J. Cheek, K. Calhoun, P. Muller, and R. F. Pommier Estrogen and Androgen Receptors as Comediators of Breast Cancer Cell Proliferation: Providing a New Therapeutic Tool Arch Surg, January 1, 2004; 139(1): 50 - 54. [Abstract] [Full Text] [PDF]

				F. Labrie, V. Luu-The, C. Labrie, A. Belanger, J. Simard, S.-X. Lin, and G. Pelletier Endocrine and Intracrine Sources of Androgens in Women: Inhibition of Breast Cancer and Other Roles of Androgens and Their Precursor Dehydroepiandrosterone Endocr. Rev., April 1, 2003; 24(2): 152 - 182. [Abstract] [Full Text] [PDF]

				M. R. I. Williams, S. Ling, T. Dawood, K. Hashimura, A. Dai, H. Li, J.-P. Liu, J. W. Funder, K. Sudhir, and P. A. Komesaroff Dehydroepiandrosterone Inhibits Human Vascular Smooth Muscle Cell Proliferation Independent of ARs and ERs J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 176 - 181. [Abstract] [Full Text] [PDF]

				S. S. Kanji, W. Kuohung, D. C. Labaree, and R. B. Hochberg Regiospecific Esterification of Estrogens by Lecithin:Cholesterol Acyltransferase J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2481 - 2488. [Abstract] [Full Text]

				H. Miyamoto, S. Yeh, H. Lardy, E. Messing, and C. Chang Delta 5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells PNAS, September 15, 1998; 95(19): 11083 - 11088. [Abstract] [Full Text] [PDF]

				R. B. Hochberg Biological Esterification of Steroids Endocr. Rev., June 1, 1998; 19(3): 331 - 348. [Abstract] [Full Text]